Maria Babak: A leap forward for patients battling recurrent or metastatic NPC

Maria Babak shared a post on LinkedIn by Babak Lab adding:

“This improvement in nasopharyngeal cancer treatment could mean a significant leap forward for patients battling recurrent or metastatic NPC. The new chemotherapy regimen, nab-TPC improves survival rates and also comes with fewer harsh side effects. It’s a game-changer in oncology!

Don’t miss this post if you’re passionate about oncology or want to stay ahead in healthcare innovation!”

Quoting Babak Lab’s post below:

“Clinical Monday Promising Results in Cancer Treatment: A New Standard for Nasopharyngeal Carcinoma 

Exciting news from a recent Phase 3 clinical trial comparing chemotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma (NPC) reveals a promising new standard of care!

Nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) demonstrated significantly better outcomes than the traditional gemcitabine-cisplatin regimen:

• Progression-Free Survival: Extended from 7.7 to 11.3 months
• Response Rate: 83% for nab-TPC vs. 63% for gemcitabine-cisplatin
• Longer Duration of Response: 10.8 vs. 6.9 months
• Fewer Side Effects: Lower rates of severe leukopenia, neutropenia, and anemia
• No Treatment-Related Deaths

With these positive results, nab-TPC could become the first-line treatment for recurrent/metastatic NPC, offering patients extended progression-free survival and improved safety.

Read more.

Stay tuned for more updates as we follow the long-term impacts of this revolutionary treatment!”

Source: Maria Babak/LinkedIn and Babak Lab/LinkedIn

Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.